Literature DB >> 35459444

Symptom subtypes and risk of incident cardiovascular and cerebrovascular disease in a clinic-based obstructive sleep apnea cohort.

A J Hirsch Allen1, Rachel Jen1, Diego R Mazzotti2, Brendan T Keenan3, Sebastian D Goodfellow4, Carolyn M Taylor1, Patrick Daniele5, Bernardo Peres6, Yu Liu1,7, Morvarid Mehrtash1, Najib T Ayas1.   

Abstract

STUDY
OBJECTIVES: Patients with obstructive sleep apnea (OSA) are at increased risk of cardiovascular and cerebrovascular disease, but predicting those at greatest risk is challenging. Using latent class analysis, patients with OSA can be placed into discrete symptom subtypes. The aim of this study was to determine whether symptom subtypes are associated with future cerebrovascular disease in patients with OSA in a clinic-based cohort.
METHODS: Patients with suspected OSA referred for a polysomnogram at an academic sleep center completed a comprehensive symptom survey. Patients with OSA (apnea-hypopnea index ≥ 5 events/h) were then placed into symptom subtypes based on responses to survey questions using latent class analysis. Cardiovascular events (stroke, myocardial infarction, unstable angina, bypass grafting, percutaneous coronary intervention, cardiac resynchronization therapy, defibrillation) occurring within 8 years of polysomnogram were identified by linkage to provincial health databases.
RESULTS: 1,607 patients were studied, of whom 1,292 had OSA. One hundred forty first events occurred within 8 years of polysomnogram. Patients in the excessively sleepy with disturbed sleep subtype had a significantly increased rate of events compared to the minimally symptomatic subtype (hazard ratio = 2.25, 95% confidence interval: 1.02-4.94; P = .04). Two symptoms (restless legs and dozing off or sleeping while talking to someone) were significantly associated with future risk of cerebrovascular disease (hazard ratio = 1.68, 1.12-2.49 and 4.23, 1.61-11.16, respectively).
CONCLUSIONS: Patients with OSA in the clinic who are in the excessively sleepy with disturbed sleep subtype are significantly more likely to have a future cardiovascular event. This underscores the importance of understanding clinical heterogeneity and incorporating symptom subtype definitions into routine clinical care. CITATION: Allen AJH, Jen R, Mazzotti DR, et al. Symptom subtypes and risk of incident cardiovascular and cerebrovascular disease in a clinic-based obstructive sleep apnea cohort. J Clin Sleep Med. 2022;18(9):2093-2102.
© 2022 American Academy of Sleep Medicine.

Entities:  

Keywords:  OSA; cardiovascular events; obstructive sleep apnea; sleepiness; symptoms

Mesh:

Year:  2022        PMID: 35459444      PMCID: PMC9435337          DOI: 10.5664/jcsm.9986

Source DB:  PubMed          Journal:  J Clin Sleep Med        ISSN: 1550-9389            Impact factor:   4.324


  26 in total

1.  Co-morbidity data in outcomes research: are clinical data derived from administrative databases a reliable alternative to chart review?

Authors:  K H Humphries; J M Rankin; R G Carere; C E Buller; F M Kiely; J J Spinelli
Journal:  J Clin Epidemiol       Date:  2000-04       Impact factor: 6.437

2.  Administrative hospitalization database validation of cardiac procedure codes.

Authors:  Douglas S Lee; Audra Stitt; Xuesong Wang; Jeffery S Yu; Yana Gurevich; Kori J Kingsbury; Peter C Austin; Jack V Tu
Journal:  Med Care       Date:  2013-04       Impact factor: 2.983

3.  Recognizable clinical subtypes of obstructive sleep apnea across international sleep centers: a cluster analysis.

Authors:  Brendan T Keenan; Jinyoung Kim; Bhajan Singh; Lia Bittencourt; Ning-Hung Chen; Peter A Cistulli; Ulysses J Magalang; Nigel McArdle; Jesse W Mindel; Bryndis Benediktsdottir; Erna Sif Arnardottir; Lisa Kristin Prochnow; Thomas Penzel; Bernd Sanner; Richard J Schwab; Chol Shin; Kate Sutherland; Sergio Tufik; Greg Maislin; Thorarinn Gislason; Allan I Pack
Journal:  Sleep       Date:  2018-03-01       Impact factor: 5.849

Review 4.  Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis.

Authors:  Adam V Benjafield; Najib T Ayas; Peter R Eastwood; Raphael Heinzer; Mary S M Ip; Mary J Morrell; Carlos M Nunez; Sanjay R Patel; Thomas Penzel; Jean-Louis Pépin; Paul E Peppard; Sanjeev Sinha; Sergio Tufik; Kate Valentine; Atul Malhotra
Journal:  Lancet Respir Med       Date:  2019-07-09       Impact factor: 30.700

5.  The different clinical faces of obstructive sleep apnoea: a cluster analysis.

Authors:  Lichuan Ye; Grace W Pien; Sarah J Ratcliffe; Erla Björnsdottir; Erna Sif Arnardottir; Allan I Pack; Bryndis Benediktsdottir; Thorarinn Gislason
Journal:  Eur Respir J       Date:  2014-09-03       Impact factor: 16.671

6.  Symptom-Based Subgroups of Koreans With Obstructive Sleep Apnea.

Authors:  Jinyoung Kim; Brendan T Keenan; Diane C Lim; Seung Ku Lee; Allan I Pack; Chol Shin
Journal:  J Clin Sleep Med       Date:  2018-03-15       Impact factor: 4.062

7.  Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study.

Authors:  Jose M Marin; Santiago J Carrizo; Eugenio Vicente; Alvar G N Agusti
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

8.  The Interaction of Obesity and Nocturnal Hypoxemia on Cardiovascular Consequences in Adults with Suspected Obstructive Sleep Apnea. A Historical Observational Study.

Authors:  Tetyana Kendzerska; Richard S Leung; Andrea S Gershon; George Tomlinson; Najib Ayas
Journal:  Ann Am Thorac Soc       Date:  2016-12

9.  Objective measurement of patterns of nasal CPAP use by patients with obstructive sleep apnea.

Authors:  N B Kribbs; A I Pack; L R Kline; P L Smith; A R Schwartz; N M Schubert; S Redline; J N Henry; J E Getsy; D F Dinges
Journal:  Am Rev Respir Dis       Date:  1993-04

10.  A Validation Study of Four Different Cluster Analyses of OSA and the Incidence of Cardiovascular Mortality in a Hispanic Population.

Authors:  Gonzalo Labarca; Jorge Dreyse; Constanza Salas; Francisca Letelier; Jorge Jorquera
Journal:  Chest       Date:  2021-07-02       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.